Abstract
Extramedullary myeloma (EMM) refers to the presence of clonal plasma cells outside the bone marrow in a patient with multiple myeloma (MM). The development of novel agents and hematopoietic stem cell transplantation (HSCT) significantly extend the survival of patients with MM, but none of the current treatments can completely overcome the adverse prognosis of EMM, and the prognosis of EMM is still poor. It is important to understand the current status of EMM treatments and explore new therapies to improve the prognosis of EMM. This article summarizes the recent advances in the treatment of EMM, including chemotherapy, HSCT, cellular immunotherapy and molecular targeted therapy. Key words: Multiple myeloma; Antineoplastic combined chemotherapy protocols; Hematopoietic stem cell transplantation; Molecular targeted therapy; Extramedullary myeloma; Chimeric antigen receptor-based immunotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
